If the company replied to emails and calls the price would be $1.
I had similar experiences.
Company is totally focused on its tasks and assumes market will take care of itself.
Big pharma candidate would not have requested second lot of tests if it were not interested.
Great to see CEO decided to produce test internally. Apparantly not very costly to do and its right up their alley.
I run a model on some of these small cap tech/bio stocks. This tops my list.
If the company replied to emails and calls the price would be...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $187.1K | 634.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 81754 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 15.57pm 27/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |